{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"64","value":"14.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63","value":"23.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70","value":"32.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56","value":"48.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Cycle 9"}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"}],"units":"Participants"}],"description":"Cmin of Ramucirumab following administration every 3 weeks.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Docetaxel"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 2, 3, 5 and 9 (Predose and Postdose)","title":"PK: Minimum Concentration (Cmin) of Ramucirumab","type":"SECONDARY","unitOfMeasure":"μg/mL"}